Consensus on rapid screening for prodromal Alzheimer's disease in China  

作　　者：Lin Huang Qinjie Li Yao Lu Fengfeng Pan Liang Cui Ying Wang Ya Miao Tianlu Chen Yatian Li Jingnan Wu Xiaochun Chen Jianping Jia Qihao Guo 

机构地区：[1]Department of Gerontology,Shanghai Sixth People's Hospital Afiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China [2]Center for Translational Medicine and Shanghai Key Laboratory of Diabetes Mellitus,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China [3]shanghai BestCovered,Shanghai,China [4]ADepartment of Neurology,Fujan Medical University Union Hospital,Fuzhou,China [5]Department of Neurology,National Clinical Research Center for Geriatric Diseases,Beijing,China

出　　处：《General Psychiatry》2024年第1期1-16,共16页综合精神医学（英文）

基　　金：the National Natural Science Foundation of China(82171198,U20A20354);the Sci-Tech Innovation 2030 Agenda of China(2022ZD0211603).

摘　　要：Alzheimer's disease(AD)is a common cause of dementia,characterised by cerebral amyloid-βdeposition,pathological tau and neurodegeneration.The prodromal stage of AD(pAD)refers to patients with mild cognitive impairment(MCl)and evidence of AD's pathology.At this stage,disease-modifying interventions should be used to prevent the progression to dementia.Given the inherent heterogeneity of MCl,more specific biomarkers are needed to elucidate the underlying AD's pathology.Although the uses of cerebrospinal fluid and positron emission tomography are widely accepted methods for detecting AD's pathology,their clinical applications are limited by their high costs and invasiveness,particularly in low-income areas in China.Therefore,to improve the early detection of Alzheimer's disease(AD)pathology through cost-effective screening methods,a panel of 45neurologists,psychiatrists andgerontologistswas invited to establish a formal consensus on the screening of pAD in China.The supportive evidence and grades of recommendations are based on a systematic literature review andfocus group discussion.National meetings were held to allow participants to review,vote and provide their expert opinions to reach a consensus.A majority(two-thirds)decision was used for questions for which consensus could not be reached.Recommended screening methods are presented in this publication,including neuropsychological assessment,peripheral biomarkers and brain imaging.In addition,a general workflow for Screening pAD in China is established,which will help clinicians identify individuals at high risk and determine therapeutic targets.

关 键 词：ALZHEIMER INCOME SCREENING 

分 类 号：R749.16[医药卫生—神经病学与精神病学]